
OptimizeRx Corp (OPRX) Stock Forecast & Price Target
OptimizeRx Corp (OPRX) Analyst Ratings
Bulls say
OptimizeRx Corp demonstrates a strong potential for revenue growth, with expectations of increasing revenue in the high teens to low twenties as the trend shifts from in-person to digital interactions in the pharma/provider landscape. The company's current operational capabilities support a substantial revenue run-rate of approximately $150 million, indicating built-in operating leverage that bodes well for future performance. With gross margins reaching 74.8% and record EBITDA of $12 million, significantly surpassing estimates, OptimizeRx is positioned to rebound robustly as it capitalizes on its integrated offerings and the anticipated success of its RWE-AI product cycle.
Bears say
OptimizeRx's stock outlook is negatively impacted by a significant reduction in its 2026 revenue guidance, which has been lowered to $109 million-$114 million from previous expectations of $118 million-$124 million, reflecting ongoing headwinds primarily from large pharma clients facing pricing initiatives. The company anticipates weak revenue and earnings results through the first half of 2026, forecasting declines around 10% year-over-year in the first two quarters, amidst escalating pressure stemming from the pharmaceutical industry's struggle with recent pricing policies. Additionally, notable declines in net revenue retention and a decrease in visibility regarding contracted revenues contribute to a more challenging growth environment, with EBITDA margins projected to decrease due to this revenue deceleration.
This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.
OptimizeRx Corp (OPRX) Analyst Forecast & Price Prediction
Start investing in OptimizeRx Corp (OPRX)
Order type
Buy in
Order amount
Est. shares
0 shares